BMC medicine
Trends in lipid-lowering therapies in acute coronary syndromes after Chinese new insurance policy: a real-world analysis.
Xin Zhao, Shujing Wu, Zhen Wang, Luning Zhou, Peng Zhang, Huajie Xu, Mengmeng Yu, Zhiyong Qi, Lili Xu, Neng Dai, Hongbo Yang, Yingnan Bai, Bing Fan, Juying Qian, Hongyi Wu
Published: 202610.1186/s12916-026-04616-2
Abstract
BACKGROUND: The Chinese new insurance policy for proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), which made it more affordable to patients from January 1, 2022, may change lipid-lowering therapy (LLT) pattern for acute coronary syn…
Preview only. Read the full abstract at the source